Harrow Inc. Common Stock (HROW)
Stock · NASDAQ · Health Care
$27.29as of 10/16/2026
Price chart
Active signals
HROW Signal Track Record
How signals performed across all stocks →What HROW's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 44 | +1.7% | 52% | September 11, 2026 |
| Bollinger Band Breakout | 29 | +4.1% | 55% | July 17, 2026 |
| Bollinger Band Breakdown | 21 | +6.5% | 62% | August 28, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -7.3% | 22% | August 25, 2026 |
| Any 20-session window (baseline) | +3.9% | 55% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About HROW
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEV…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 373
- Website
- www.harrow.com/
Fundamentals
- 1-day range
- $27.03$28.91
- Market cap
- $1.49B
- P/E (trailing)
- —
- P/E (forward)
- 10.37
- EPS (trailing)
- $-1.00
- Dividend yield
- —
- Beta
- 0.13
- Avg. volume
- 584.9K
How Harrow Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 2, 2026 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
Harrow Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- HROWHarrow Inc. Common Stock$27.28▼ 5.11%Market cap $1.49BP/E —$26.96$54.85
- XNCRXencor Inc. Common Stock$22.85▼ 4.79%Market cap $1.48BP/E —$10.38$30.61
- AVBPArriVent BioPharma Inc. Common Stock$16.66▼ 0.77%Market cap $1.44BP/E —$11.36$35.83
- PAHCPhibro Animal Health Corporation Class A Common Stock$38.82▲ 2.21%Market cap $1.44BP/E 15.44$28.25$60.08
- INVAInnoviva Inc. Common Stock$20.78▼ 0.38%Market cap $1.56BP/E 4.25$16.52$25.15
- TRAXFirst Tracks Biotherapeutics Inc. Ordinary Shares$34.46▼ 4.38%Market cap $1.58BP/E —$14.72$49.91
- LBRXLB Pharmaceuticals Inc Common Stock$36.74▲ 0.14%Market cap $1.38BP/E —$14.32$50.16
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| HROW Harrow Inc. Common Stock | $1.49B | — | $27.28 | ▼ 5.11% | $26.96$54.85 |
| XNCR Xencor Inc. Common Stock | $1.48B | — | $22.85 | ▼ 4.79% | $10.38$30.61 |
| AVBP ArriVent BioPharma Inc. Common Stock | $1.44B | — | $16.66 | ▼ 0.77% | $11.36$35.83 |
| PAHC Phibro Animal Health Corporation Class A Common Stock | $1.44B | 15.44 | $38.82 | ▲ 2.21% | $28.25$60.08 |
| INVA Innoviva Inc. Common Stock | $1.56B | 4.25 | $20.78 | ▼ 0.38% | $16.52$25.15 |
| TRAX First Tracks Biotherapeutics Inc. Ordinary Shares | $1.58B | — | $34.46 | ▼ 4.38% | $14.72$49.91 |
| LBRX LB Pharmaceuticals Inc Common Stock | $1.38B | — | $36.74 | ▲ 0.14% | $14.32$50.16 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Do Options Traders Know Something About Harrow Stock We Don't?Yahoo · 10/9/2026
- Harrow: Q3 Needs To Prove The Turnaround Is RealSeekingAlpha · 10/8/2026
- Is Harrow (HROW) Undervalued On Growing Conference Buzz Around Its Ophthalmic Pipeline?Yahoo · 10/8/2026
- BTIG Reiterates Buy on Harrow, Maintains $63 Price Targetbenzinga · 10/7/2026
- BTIG Reiterates Buy on Harrow, Maintains $63 Price TargetBenzinga · 10/7/2026
- Harrow Closes Acquisition of TYRVAYA®Yahoo · 10/5/2026
- Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAOYahoo · 9/30/2026
- Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts ApproachBenzinga · 9/25/2026
Insider Activity
Insider Actions →- Shojaei Amir · August 14, 2026 · Option Exercise11.3K @ $35.96
- Shojaei Amir · August 14, 2026 · Sale11.3K @ $40
- Lauren P. Silvernail · June 18, 2026 · Grant5.2K
- Sternberg Perry J. · June 18, 2026 · Grant5.2K
- Adrienne L. Graves · June 18, 2026 · Grant5.2K
- Adrienne L. Graves · May 18, 2026 · Buy1.0K @ $31.07
- Lauren P. Silvernail · May 18, 2026 · Buy1.0K @ $31
- Shojaei Amir · May 15, 2026 · Grant10.0K
- Andrew R. Boll · May 14, 2026 · Buy3.5K @ $29.9
- Mark L. Baum · May 14, 2026 · Buy10.0K @ $30.2
Institutional Ownership
March 31, 2026
- Total shares held
- 22.44M
- Total value held
- $789.21M
- Institutional holders
- 213
- Unknown2.83M
- Unknown2.55M
- Unknown1.60M
- Unknown1.47M
- Unknown1.40M
- Unknown1.12M
- Unknown855.0K
- Unknown852.0K
- Unknown644.9K
- Unknown579.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Harrow (HROW) gains analyst support and conference buzz amid turnaround focus
Recent coverage highlights growing attention on Harrow’s ophthalmic pipeline, with analysts maintaining a $63 price target and an average target of $65. A recent conference has generated buzz, while options activity suggests market participants are watching the stock closely. The company’s Q3 results are expected to confirm whether the turnaround plan is taking hold.
Harrow (HROW) gains analyst support and conference buzz amid turnaround focus. Recent coverage highlights growing attention on Harrow’s ophthalmic pipeline, with analysts maintaining a $63 price target and an average target of $65. A recent conference has generated buzz, while options activity suggests market participants are watching the stock closely. The company’s Q3 results are expected to confirm whether the turnaround plan is taking hold.